Stem Cell Breakthrough Could Reopen Clone Wars
By Editorial,
New Scientist
| 01. 29. 2014
It didn't take long after Dolly the sheep was cloned in 1996 for maverick scientists to start talking about cloning humans.
One, Severino Antinori, attracted
global condemnation when he announced plans to use cloning to help infertile couples. Critics of the idea argued that vital questions had to be answered first: about the health of the progeny, their identity and, for those so inclined, the spiritual dimensions.
Those clones never arrived: the technology was not up to it. But now comes news that biologists have turned mature animal cells into something resembling "totipotent" stem cells – and are trying to do the same with human cells (see "
Stem cell power unleashed after 30 minute dip in acid").
Totipotent cells are the most versatile of all stem cells; a single one can develop into an embryo with a placenta, and hence give rise to a fully formed animal – in other words, a clone. The researchers do not use the word "totipotent" and have no stated intention of cloning a human. But the research seems to have reopened the...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...